复宏汉霖获润新生物BRAF抑制剂权益,合作金额**超10亿元

2021-04-04 秘丛丛 亿欧

复宏汉霖宣布与润新生物就BRAF V600E抑制剂RX208达成一项独家许可合作,复宏汉霖获得该产品在中国(包括中国香港、中国澳门和中国台湾)进行研究、开发、生产和商业化等的独家权利。

复宏汉霖宣布与润新生物就BRAF V600E抑制剂RX208达成一项独家许可合作,复宏汉霖获得该产品在中国(包括中国香港、中国澳门和中国台湾)进行研究、开发、生产和商业化等的独家权利。

根据合作协议,润新生物将获得9750万元的首付款,最高可达约10.8亿元的相关临床开发、注册和销售里程碑付款,以及产品上市后的销售提成。复宏汉霖表示,此次合作是复宏汉霖加速多元化创新的重要战略布局,有望增强产品靶点和种类多样性,与复宏汉霖多款自主研发药物相互补充,进一步完善现有创新管线。

此次合作的BRAF靶点产品RX208拥有全新的化学母核结构,临床上拟用于治疗BRAF V600E突变阳性、不适合手术的局部晚期或转移性恶性实体瘤,目前处于临床1期阶段。临床前研究结果表明,该产品具有显着的肿瘤抑制活性及良好的安全性。

BRAF蛋白是MAPK/ERK信号通路中重要的上游调节因子,其V600E突变可激活下游MEK蛋白,进一步引起肿瘤细胞生长、增殖和侵袭,易发生于结直肠癌、甲状腺癌、黑色素瘤等多个癌种中,该类患者往往预后较差。

结直肠癌是中国第二高发的恶性肿瘤,2020年新发患者约55.5万人,有5-15%存在该突变。研究表明,BRAF V600E抑制剂联合EGFR单抗能够有效改善该类患者的生存现状及预后。目前已有上市的BRAF V600E抑制剂用于结直肠癌、黑色素瘤、罕见病脂质肉芽肿(Erdheim-Chester Disease, ECD)等的治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852629, encodeId=84f61852629a1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 30 20:03:34 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936831, encodeId=1b43193683127, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Thu Dec 09 22:03:34 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355029, encodeId=01bb1355029d8, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418453, encodeId=655214184536e, content=<a href='/topic/show?id=c2ae42630ba' target=_blank style='color:#2F92EE;'>#复宏汉霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42630, encryptionId=c2ae42630ba, topicName=复宏汉霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dd53361593, createdName=FukaiBao, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530194, encodeId=ebb21530194b3, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3668, encryptionId=6b4d3668c3, topicName=BRAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=292d12051665, createdName=hjwang83, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=)]
    2021-07-30 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1852629, encodeId=84f61852629a1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 30 20:03:34 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936831, encodeId=1b43193683127, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Thu Dec 09 22:03:34 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355029, encodeId=01bb1355029d8, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418453, encodeId=655214184536e, content=<a href='/topic/show?id=c2ae42630ba' target=_blank style='color:#2F92EE;'>#复宏汉霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42630, encryptionId=c2ae42630ba, topicName=复宏汉霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dd53361593, createdName=FukaiBao, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530194, encodeId=ebb21530194b3, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3668, encryptionId=6b4d3668c3, topicName=BRAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=292d12051665, createdName=hjwang83, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1852629, encodeId=84f61852629a1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 30 20:03:34 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936831, encodeId=1b43193683127, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Thu Dec 09 22:03:34 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355029, encodeId=01bb1355029d8, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418453, encodeId=655214184536e, content=<a href='/topic/show?id=c2ae42630ba' target=_blank style='color:#2F92EE;'>#复宏汉霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42630, encryptionId=c2ae42630ba, topicName=复宏汉霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dd53361593, createdName=FukaiBao, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530194, encodeId=ebb21530194b3, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3668, encryptionId=6b4d3668c3, topicName=BRAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=292d12051665, createdName=hjwang83, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=)]
    2021-04-05 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1852629, encodeId=84f61852629a1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 30 20:03:34 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936831, encodeId=1b43193683127, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Thu Dec 09 22:03:34 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355029, encodeId=01bb1355029d8, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418453, encodeId=655214184536e, content=<a href='/topic/show?id=c2ae42630ba' target=_blank style='color:#2F92EE;'>#复宏汉霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42630, encryptionId=c2ae42630ba, topicName=复宏汉霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dd53361593, createdName=FukaiBao, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530194, encodeId=ebb21530194b3, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3668, encryptionId=6b4d3668c3, topicName=BRAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=292d12051665, createdName=hjwang83, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1852629, encodeId=84f61852629a1, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 30 20:03:34 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936831, encodeId=1b43193683127, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Thu Dec 09 22:03:34 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355029, encodeId=01bb1355029d8, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418453, encodeId=655214184536e, content=<a href='/topic/show?id=c2ae42630ba' target=_blank style='color:#2F92EE;'>#复宏汉霖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42630, encryptionId=c2ae42630ba, topicName=复宏汉霖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dd53361593, createdName=FukaiBao, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530194, encodeId=ebb21530194b3, content=<a href='/topic/show?id=6b4d3668c3' target=_blank style='color:#2F92EE;'>#BRAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3668, encryptionId=6b4d3668c3, topicName=BRAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=292d12051665, createdName=hjwang83, createdTime=Mon Apr 05 16:03:34 CST 2021, time=2021-04-05, status=1, ipAttribution=)]

相关资讯

Nat Med:黑色素瘤新辅助疗法病理反应和生存率的汇总分析研究

由于全身疗法的不断改进,在过去十年里,转移性黑色素瘤患者的临床结局得到显著的改善。

J Immunother Cancer:晚期黑色素瘤抗PD-1免疫治疗时的耐药类型和影像学变化

晚期黑色素瘤抗PD-1免疫治疗时的耐药类型和影像学变化

如何治疗PD-1难治性眼部黑色素瘤?抗CD40抗体YH003联合Toripalimab

YH003可促进抗原呈递细胞上的CD40活化,从而刺激抗肿瘤T细胞的效应因子。

君实PD-1为何与阿斯利康合作?核心市场如何界定?回应来了……

君实生物与阿斯利康近日签署的关于PD-1药物特瑞普利单抗不同适应症在中国不同区域市场达成的推广合作协议引起了行业关注。

Br J Cancer:倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗

在过去的十年中,新型的全身治疗选择已应用于转移性黑色素瘤的治疗中。

黑色素瘤双靶、双适应症药物2020年医保价格正式实施,助益更多患者减轻负担

自2021年3月1日起,2020年新版国家医保药品目录在全国范围内正式启用,全国多省市陆续开展药品直接挂网工作。其中,诺华肿瘤治疗黑色素瘤的双靶治疗药物——泰菲乐?(甲磺酸达拉